Lineage Cell Therapeutics, Inc.

AMEX:LCTX

Biotechnology

Healthcare
$0.84 -2.80%

-$0.04 today

Market cap
$212.10M
Beta
1.51
P/E (TTM)
-4.6
EPS (TTM)
-$0.26
52W Low $0.85High $2.09

Volume 1.22M

Average 1.19M

LCTX Common Stock

The par or stated value of issued common shares, plus paid-in capital where reported together.

Lineage Cell Therapeutics, Inc.AMEX: LCTX

Common Stock · Q1 FY2026 · quarter ended Mar 2026

Common stock rises 8.2% from a year ago

Common stock stood at $529.66M at the end of Q1 FY2026, up 8.2% from a year earlier and up 2.8% from the prior quarter. Over 3 fiscal years it compounded at +5.4% a year.

Context

  • Common stock amounted to 483.6% of total assets at the end of Q1 FY2026, up 45.7 pp from a year earlier.
  • Common stock increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether common stock keeps rising in the next quarterly balance sheet after a +8.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$529.66M+2.8% QoQ
Last fiscal yearDec 2025
$515.47M+6.3% YoY
Year agoMar 2025
$489.31M+8.2% since
Common Stock past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+8.2%——
1 year+6.3%——
3-year CAGR+5.4%——
5-year CAGR——
10-year CAGR——

Common Stock history

USD · from the balance sheet

Latest · FY2025
515.47M USD
Year-over-year change
+6.3%
4-year CAGR
+4.4%

Common Stock vs competitors

How LCTX compares with its peers on the latest reported figures

  • LCTX's Mar 2026 common stock of $529.66M is the 2nd highest of the 4 companies compared; the peer median is $18K.
  • Its year-over-year change of +8.2% is the 3rd highest of 4, against a peer median of +50.0%.
  • Common stock amounts to 483.6% of total assets for LCTX, versus a peer median of 0.0%.
LCTX Competitors Peer median
Common Stock for LCTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MESOMesoblast LimitedJun 2026$1.53B +1.5%+7.0%198.0%
LCTXLineage Cell Therapeutics, Inc.Mar 2026$529.66M +8.2%+5.4%483.6%
IPSCCentury Therapeutics, Inc.Mar 2026$18K +100.0%+14.5%0.0%
CELUCelularity Inc.Dec 2025$3K +50.0%-41.5%0.0%
Peer median (excluding LCTX) $18K+50.0%+7.0%0.0%

Competitors are the stored peer set for LCTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents55.74M11.36M35.44M45.79M40.79M
Short-term Investments2.62M46.52M50K2.02M14.99M
Net Receivables51.14M297K745K638K1.56M
Inventory00000
Other Current Assets2.05M1.83M2.2M2.55M1.81M
Total Current Assets111.55M60M38.44M51M59.16M
Property, Plant & Equipment (Net)4.87M5.67M4.77M4.4M4.7M
Goodwill10.67M10.67M10.67M10.67M10.67M
Intangible Assets46.82M46.69M46.56M46.54M31.7M
Long-term Investments0581K000
Tax Assets0(581K)005.8M
Other Non-current Assets630K627K577K614K558K
Total Non-current Assets63M63.66M62.58M62.22M53.43M
Total Assets174.55M123.66M101.02M113.22M112.58M
Account Payables3.54M2.39M2.05M1.17M2.34M
Short-term Debt00000
Tax Payables00000
Deferred Revenue18.12M9.42M10.81M7.39M3.33M
Other Current Liabilities2.54M3.83M3.12M3.07M3.74M
Total Current Liabilities47.12M18.98M17.96M13.98M11.37M
Long-term Debt00000
Deferred Tax Liabilities2.08M2.08M273K273K22K
Deferred Revenue (Non-current)32.45M27.73M18.69M14.43M12.38M
Other Non-current Liabilities30K2K06.16M43.91M
Total Non-current Liabilities36.53M32.75M21.04M22.23M57.87M
Total Liabilities83.65M51.73M39M36.21M69.24M
Common Stock434.53M440.28M451.34M484.72M515.47M
Retained Earnings(337.1M)(363.37M)(384.86M)(403.47M)(467M)
Accumulated OCI(5.21M)(3.57M)(3.07M)(2.88M)(3.92M)
Other Stockholders Equity00000
Minority Interest(1.32M)(1.4M)(1.4M)(1.37M)(1.2M)
Total Equity90.9M71.94M62.02M77.01M43.35M
Total Debt2.8M3.9M2.95M2.51M2.42M
Net Debt(52.94M)(7.46M)(32.49M)(43.28M)(38.37M)

Lineage Cell Therapeutics, Inc.

AMEX:LCTX

Intrinsic Alpha fair value

Locked

Current Price

$0.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.